NEW YORK (GenomeWeb News) – Protein Sciences has licensed its FluBiok recombinant influenza vaccine to Japanese biotech UMN Pharma to make and sell the product in that market.
Terms of the deal call for PSC to transfer technology to UMN, which will register, manufacture, market, and sell the vaccine in Japan for annual and pandemic use.
One the test is registered with Japanese regulators, UMN will buy commercial quantities of FluBiok from PSC until a commercial manufacturing facility is available in the country.
The license terms include a multimillion-dollar upfront payment and double-digit royalties, PSC said.
FluBiok has received "accelerated approval" status from the US Food and Drug Administration and PSC said it expects to file a Biologics License Application with the agency in early 2007.